Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated:  12/31/1969
University of N C at Chapel Hill Physician Office Building
mi
from
Chapel Hill, NC
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status: Enrolling
Updated: 12/31/1969
University of N C at Chapel Hill Physician Office Building
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
St. Jude Heritage Medical Group
mi
from
Fullerton, CA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
St. Jude Heritage Medical Group
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Care Assoc Med Group
mi
from
Los Angeles, CA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Care Assoc Med Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Coastal Integrative Cancer Care
mi
from
San Luis Obispo, CA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Coastal Integrative Cancer Care
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Holycross Medical Group
mi
from
Fort Lauderdale, FL
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Holycross Medical Group
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Healthcare System
mi
from
Hollywood, FL
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Healthcare System
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northeast Georgia Cancer Care
mi
from
Athens, GA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University Cancer Center
mi
from
Indianapolis, IN
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Health Research
mi
from
Saint Louis, MO
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Health Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Henderson, NV
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Carolinas HealthCare System
mi
from
Charlotte, NC
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Carolinas HealthCare System
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Charleston Hematology Oncology, PA
mi
from
Charleston, SC
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Charleston Hematology Oncology, PA
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The West Clinic, PC
mi
from
Memphis, TN
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northern Utah Associates
mi
from
Ogden, UT
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northern Utah Associates
mi
from
Ogden, UT
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties
mi
from
Lakewood, WA
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties
mi
from
Lakewood, WA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UZ Brussel
mi
from
Brussel,
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UZ Brussel
mi
from
Brussel,
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Rady Children's Hospital
mi
from
San Diego, CA
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Rady Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Connecticut Children's Hospital
mi
from
Hartford, CT
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Connecticut Children's Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Arnold Palmer Hospital for Children
mi
from
Orlando, FL
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Arnold Palmer Hospital for Children
mi
from
Orlando, FL
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Helen DeVos Children's Hospital
mi
from
Grand Rapids, MI
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Helen DeVos Children's Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Levine Children's Hospital
mi
from
Charlotte, NC
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Levine Children's Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center and Children's Hospital
mi
from
Hershey, PA
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center and Children's Hospital
mi
from
Hershey, PA
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Monroe Carrell Jr Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Monroe Carrell Jr Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Dell Children's Blood and Cancer Center
mi
from
Austin, TX
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Dell Children's Blood and Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Texas Children's Cancer and Hematology Centers
mi
from
Houston, TX
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Texas Children's Cancer and Hematology Centers
mi
from
Houston, TX
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Primary Children's Hospital
mi
from
Salt Lake City, UT
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Primary Children's Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Cardinal Glennon Children's Medical Center
mi
from
Saint Louis, MO
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Cardinal Glennon Children's Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Randall Children's Hospital
mi
from
Portland, OR
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Randall Children's Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
American University of Beirut Medical Center
mi
from
Beirut,
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
American University of Beirut Medical Center
mi
from
Beirut,
Click here to add this to my saved trials
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated:  12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Molecular-Guided Therapy for Childhood Cancer
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Status: Enrolling
Updated: 12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
Status: Enrolling
Updated:  12/31/1969
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
Status: Enrolling
Updated: 12/31/1969
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
Status: Enrolling
Updated:  12/31/1969
MD Anderson Cancer Center at Cooper
mi
from
Voorhees, NJ
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
Status: Enrolling
Updated: 12/31/1969
MD Anderson Cancer Center at Cooper
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope /ID# 127117
mi
from
Duarte, CA
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope /ID# 127117
mi
from
Duarte, CA
Click here to add this to my saved trials